Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
1. A method for detecting cancer in vivo, the method comprising:
administering 124 I labeled 18-(p-iodophenyl)octadecyl phosphocholine to a subject; and
determining whether an organ suspected of having cancer in the subject retains a higher level of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine than surrounding regions, wherein a higher retention level of 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine indicates cancer.
2. The method of claim 1 , wherein the subject is human.
3. The method of claim 1 , comprising determining the retention of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine using PET scanning.
4. The method of claim 1 , comprising determining the retention of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine using SPECT scanning.
5. The method of claim 1 , comprising administering between about 0.5 μCi and about 500 mCi of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine to the subject.
6. The method of claim 1 , comprising administering less than 0.3 μg/kg of body weight of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine to the subject.
7. The method of claim 1 , wherein the cancer is selected from the group consisting of lung cancer, squamous cell carcinoma, melanoma, colorectal cancer, ovarian cancer, prostate cancer, glioma, breast cancer, carcinosarcoma, and pancreatic cancer.
8. A method of detection of a radiolabeled phosphocholine within a subject, comprising:
providing a subject to which 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine has been administered; and
determining retention of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine within an organ within the subject.
9. The method of claim 8 , wherein the subject is human.
10. The method of claim 8 , wherein the subject is suspected of having cancer.
11. The method of claim 8 , comprising determining the retention of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine using PET scanning.
12. The method of claim 8 , comprising determining the retention of the 124 I-labeled 18-(p-iodophenyl)octadecyl phosphocholine using SPECT scanning.
13. The method of claim 10 , wherein the cancer is selected from the group consisting of lung cancer, squamous cell carcinoma, melanoma, colorectal cancer, ovarian cancer, prostate cancer, glioma, breast cancer, carcinosarcoma, and pancreatic cancer.